Asterias Biotherapeutics stem cell study for SCI shows promising results: 4 notes

Asterias Biotherapeutics’ SCiStar Phase 1/2a clinical study yielded positive outcomes for patients with complete cervical spinal cord injury.

Advertisement

Here are four notes:

 

1. The nine-month study tested the efficacy and safety study of AST-OPC1, a human stem cell-based treatment for SCI patients.

 

2. Researchers saw three out of six patients, treated with 10 million cells, achieved two motor levels of improvement over baseline on at least one side following treatment.

 

3. All six patients experienced at least one motor level of improvement on at least one side.

 

4. Researchers presented the data at a pre-meeting workshop at the International Society for Stem Cell Research 2017 Annual Meeting in Boston from June 14 to June 17.

 

More articles on spine:
How to save up to $422 on adult spinal deformity surgery: 5 key points
Drs. Ashish Patel, Elian Shepherd perform simultaneous surgery to lower complications: 5 insights
Orthopedic spine surgeon Dr. Max Burrs dies at 76

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Watch On-Demand Webinar

ASC development + private equity: How to build value from day one

Presenters: Andrew HrankaWendy Bruno Thomson, MBA, LHARichard Romero, CVA, ABV, FHFMA, PAHM

Advertisement

Next Up in Spine

Advertisement

Comments are closed.